Cargando…

Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis

BACKGROUND: Given the controversial roles of FMS-like tyrosine kinase 3 inhibitors (FLT3i) in various treatment stages of acute myeloid leukemia (AML), this study was designed to assess this problem and further explored which FLT3i worked more effectively. METHODS: A systematic review, meta-analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Qingyu, He, Shujiao, Yu, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209493/ https://www.ncbi.nlm.nih.gov/pubmed/34150652 http://dx.doi.org/10.3389/fonc.2021.686013

Ejemplares similares

Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis
por: Xu, Qingyu, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia
por: Pazhakh, Vahid, et al.
Publicado: (2011)

FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile
por: Garciaz, Sylvain, et al.
Publicado: (2023)

Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia
por: Sun, Jie, et al.
Publicado: (2016)

Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia
por: Park, Soojin, et al.
Publicado: (2021)

Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells
por: Zhang, Yudong, et al.
Publicado: (2021)

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis
por: Chen, Kang-kang, et al.
Publicado: (2019)

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
por: Katayama, Kazuhiro, et al.
Publicado: (2018)

Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis
por: Chen, Kangkang, et al.
Publicado: (2022)

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
por: Mohanavelu, Prahathishree, et al.
Publicado: (2021)

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
por: Perrone, Salvatore, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis
por: Gómez-Llobell, Marina, et al.
Publicado: (2022)

Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
por: Selvarajan, Sathya, et al.
Publicado: (2019)

The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study
por: Abu-Tineh, Mohammad, et al.
Publicado: (2023)

Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
por: Mulas, Olga, et al.
Publicado: (2021)

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
por: Ruvolo, Peter P., et al.
Publicado: (2017)

Prognostic Significance of Fms-Like Tyrosine Kinase 3 Internal Tandem Duplication Mutation in Non-Transplant Adult Patients with Acute Myeloblastic Leukemia: A Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2020)

FLT3-TKD in the prognosis of patients with acute myeloid leukemia: A meta-analysis
por: Li, Shuping, et al.
Publicado: (2023)

Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis
por: Kronick, Olivia, et al.
Publicado: (2023)

Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD
por: Zsengellér, Zsuzsanna K., et al.
Publicado: (2019)

The incidence and prognostic effect of Fms-like tyrosine kinase 3 gene internal tandem and nucleolar phosphoprotein 1 genes in acute myeloid leukaemia: A PRISMA-compliant systematic review and meta-analysis
por: Liu, Heping, et al.
Publicado: (2020)

Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis
por: Al-Bulushi, Fatma, et al.
Publicado: (2022)

Prognostic value of receptor tyrosine kinases in malignant melanoma patients: A systematic review and meta-analysis of immunohistochemistry
por: Lei, Xuan, et al.
Publicado: (2022)

Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France
por: Pajiep, Marie, et al.
Publicado: (2021)

Regulation of expression level of fms-like tyrosine kinase-4 is related to osteoclast differentiation
por: Zhu, Yi, et al.
Publicado: (2015)

Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice
por: Della Verde, Giacomo, et al.
Publicado: (2021)

Soluble FMS-Like Tyrosine Kinase-1: Role in placenta accreta spectrum disorder
por: Lumbanraja, Sarma, et al.
Publicado: (2022)

The Endothelial Glycocalyx as a Target of Excess Soluble Fms-like Tyrosine Kinase-1
por: Schulz, Annika, et al.
Publicado: (2023)

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma
por: Shi, Binhao, et al.
Publicado: (2023)

2-Methoxyestradiol combined with ascorbic acid facilitates the apoptosis of chronic myeloid leukemia cells via the microRNA-223/Fms-like tyrosine kinase 3/phosphatidylinositol-3 kinase/protein kinase B axis
por: Zhang, Suwei, et al.
Publicado: (2022)

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
por: Pasquale, Raffaella, et al.
Publicado: (2022)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience
por: Chitanava, Tamara, et al.
Publicado: (2023)

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance
por: Imeri, Jusuf, et al.
Publicado: (2023)

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
por: Ward, Melea A., et al.
Publicado: (2015)

FMS-like tyrosine kinase 3 is required for dendritic cell development in peripheral lymphoid tissues
por: Waskow, Claudia, et al.
Publicado: (2008)

Fms-Like Tyrosine Kinase 3 Ligand Controls Formation of Regulatory T Cells in Autoimmune Arthritis
por: Svensson, Mattias N. D., et al.
Publicado: (2013)

Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia
por: Sánchez-Aranguren, Lissette C., et al.
Publicado: (2018)

Soluble Fms-Like Tyrosine Kinase-1 Is A Marker of Endothelial Dysfunction During Sepsis
por: Greco, Marilena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sk4ntkk73un287aq42l94i3eos